Human leukocyte antigen peptide-binding groove (HLA peptide-binding groove) (HLA peptide-binding groove)

The Human leukocyte antigen (HLA) peptide-binding groove is a specialized structural domain within the Major Histocompatibility Complex (MHC) molecules that plays a fundamental role in the adaptive immune system. Its primary function is to bind short peptide fragments derived from intracellular or extracellular proteins and present them on the cell surface for recognition by T-cell receptors (TCRs). This interaction allows the immune system to monitor the health of cells and distinguish between 'self' and 'non-self' (pathogenic or mutated) antigens. Due to the extreme polymorphism of HLA genes, the binding groove's architecture is highly variable among individuals, which dictates the specific repertoire of peptides an individual can present and respond to. In clinical medicine, the patient-specific HLA peptide-binding groove is a central target for personalized cancer immunotherapies, such as neoantigen vaccines and TCR-engineered T-cell (TCR-T) therapies, which aim to trigger an immune response against tumor-specific mutations. The groove is also a critical site for drug-induced hypersensitivity; certain small molecules can bind within the pocket and alter the presented peptide repertoire, leading to 'altered self' recognition and severe immune reactions. Effective therapeutic targeting of this site requires precise high-resolution HLA typing and advanced computational modeling to ensure high affinity and minimize the risk of off-target toxicity against healthy tissues.

Other names

MHC peptide-binding cleftHLA binding pocketMajor histocompatibility complex peptide-binding groovePeptide-binding region (PBR)Antigen-binding groove

The HLA peptide-binding groove functions by capturing and presenting short peptide fragments (antigens) to T-cell receptors (TCRs) to initiate an adaptive immune response. Therapeutic agents like neoantigen vaccines provide specific peptides to fill this groove, while TCR-T therapies and bispecifics (e.g., Tebentafusp) recognize the resulting peptide-HLA complex. Conversely, certain small-molecule drugs (e.g., abacavir) bind directly within the groove, altering its conformation and the repertoire of presented self-peptides, which triggers immune-mediated hypersensitivity.